Clinical Trials Logo

Renal Insufficiency clinical trials

View clinical trials related to Renal Insufficiency.

Filter by:

NCT ID: NCT00748904 Withdrawn - Liver Cirrhosis Clinical Trials

Rifaximin Versus Lactulose in Renal Failure

Start date: June 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less frequent and/or slower progression to severe hepatic encephalopathy. If one is associated with lower blood ammonia levels. And, if one is associated with lower breath hydrogen and methane levels.

NCT ID: NCT00633308 Withdrawn - Kidney Failure Clinical Trials

Phosphorus and Calcium Removal During Long Hemodialysis Treatment Sessions

hemodialysis
Start date: March 2008
Phase: Phase 2
Study type: Interventional

The purpose of this sudy is to determined the effect of dialysate volume and treatment time on phosphate and calcium removal in stage V chronickidney disease patients treated by hemodialysis using the System One (NxStage Medical, Lawrence, MA)

NCT ID: NCT00621972 Withdrawn - Acute Renal Failure Clinical Trials

AV Fistula Salvage in Advanced CKD Using Sodium Bicarbonate Prophylaxis

Start date: January 2008
Phase:
Study type: Observational

This is an observational study assessing the impact of conventional dose iodinated contrast on the renal function of advanced chronic kidney disease patients undergoing arteriovenous fistula evaluation using a standard sodium bicarbonate prophylaxis protocol. In addition, this model allows for pre and post procedure measurements of kidney function, providing a unique opportunity to assess the utility of novel biomarkers for contrast-induced kidney injury. Our primary hypothesis is that there will be no change in serum creatinine post-procedure when using a standard sodium bicarbonate prophylaxis protocol. Our secondary hypothesis is that there will be no change in urinary kidney-injury marker-1 (KIM-1) post-procedure using a standard sodium bicarbonate prophylaxis protocol. In addition, we will assess the impact of different patient characteristics on the development of contrast-induced kidney injury, such as diabetes, coronary artery disease, hypertension, and angiotensin converting enzyme inhibitor therapy.

NCT ID: NCT00548912 Withdrawn - Clinical trials for Kidney Failure, Chronic

Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease

Start date: October 2007
Phase: Phase 4
Study type: Interventional

The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass

NCT ID: NCT00483600 Withdrawn - Kidney Diseases Clinical Trials

Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction

Start date: August 2007
Phase: N/A
Study type: Interventional

To determine the appropriate dose and safety of a preventative dose of fondaparinux, an anticoagulant medication (blood thinner) in patients with kidney disease.

NCT ID: NCT00483275 Withdrawn - Aged Clinical Trials

Fall Prevention by Alfacalcidol and Training

SPALT
Start date: June 2007
Phase: Phase 4
Study type: Interventional

Objective of the study is to evaluate the effect of a multimodal therapy on the basis of current guidelines on fall prevention consisting of a 12-months intervention with Alfacalcidol and calcium, patient education and a mobility program in a group of patients 65 years of age or older with an impaired renal function in comparison to a group receiving usual care.

NCT ID: NCT00476515 Withdrawn - Clinical trials for Kidney Insufficiency

Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor

Start date: March 2007
Phase: Phase 1
Study type: Interventional

Primary Objectives: - Conversion of a positive donor specific cross-match to a living donor to a negative cross-match thereby allowing successful renal transplantation. - Transplant success or failure following the desensitization protocol. - Determination of the effect of rituximab on the kinetics of donor specific antibodies (DSA). - Determination of the effect of rituximab on the kinetics of B-cell subpopulations in peripheral blood and/or secondary lymphoid organs (lymph node biopsies at time of transplant, if available) in both responders and non-responders using flow cytometry and/or immunohistochemistry. Secondary Objectives: -Decrease in incidence of humoral rejection to less than 50 % at 1 year.

NCT ID: NCT00466882 Withdrawn - Obesity Clinical Trials

Use of the INAMED LAPBAND System to Reduce BMI's in Obese Renal Failure Patients

Start date: October 17, 2005
Phase:
Study type: Observational

The purpose of this study is to assess the use of this Lap-Band system for the purpose of promoting weight loss in renal failure patients who do not qualify as transplant candidates because of excessive BMI's

NCT ID: NCT00392132 Withdrawn - HIV Infections Clinical Trials

Impact of Screening Patients With HIV for Kidney Disease

Start date: October 2005
Phase:
Study type: Observational

The Infectious Disease Society of America has recently recommended that patients with Human Immunodeficiency Virus (HIV) be screened for kidney disease on a regular basis. Screening involves non-invasive urine and blood test and a screening program has already been initiated here in the University of Mississippi HIV clinic. This study looks at the effect of this new screening program. Our Hypothesis is that screening for kidney disease is a cost effective and important addition to the care of patients with HIV.

NCT ID: NCT00335101 Withdrawn - Diabetes Mellitus Clinical Trials

Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography

Start date: June 2006
Phase: Phase 4
Study type: Interventional

The study is to evaluate and compare the effects on kidney function of three iodinated contrast media (CM) in patients at risk of kidney damage evaluating serum creatinine (Scr) concentrations up to three days after CM administration.